Jennifer G. Allen

Special considerations must be made when treating patients infected with both HIV and hepatitis C virus.

Biosimilars face scrutiny before they can be indicated for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis.

More than half of all high resource patients are prescribed 10 or more prescription drugs.

Researchers propose new financing options to make costly drug therapies widely accessible to patients.

Major breakthroughs in hepatitis C virus research hold promise for patient care and control of viral global health crises.

Consolidated administrative services organization with national reach seeks to help independent pharmacies with managed care contracts and Star Ratings.

Caregivers should closely monitor hepatitis C infection in patients undergoing chemotherapy.

The latest Magellan Health report highlights spending trends and current pharmacy benefit issues.

Study finds more consistency is needed to ensure the safety, efficacy, and fair pricing of orphan drugs.

Researchers examine acceptance rates and factors predicting doctor acceptance of pharmacist recommendations within a Medicare Advantage Plan.

Significant low-cost generic program use is likely to be underrepresented in administrative claims data.

Adherence patterns and other risk factors predict increased utilization of acute care by outpatients with cancer pain.

Research addresses whether the prior authorization process creates a barrier to timely and effective care for hepatitis C.

Nearly 1 of 4 initial requests for Harvoni were denied in a recent study of hepatitis C drug coverage.

Comprehensive medication management programs may improve drug adherence across multiple chronic conditions.

With the increasing use of novel therapies for multiple myeloma, benchmarks are needed to assess the value of these options.

Researchers created a model framework to compare costs of 7 common regimens to treat relapsed and/or refractory multiple myeloma.

The management of individual chemotherapy regimens by pharmacists improves safety by reducing medication errors.

The impact of pharmacist-led medication management services in the treatment chronic diseases.

Treatments for back disorders and osteoarthritis are the greatest expenses for both the high resource patient and general populations.

The most commonly used biologic drugs to treat RA include etanercept, adalimumab, infliximab, and abatacept

A summary of the clinical potential of biosimilar therapies and special considerations for older patients with cancer.

Biologic agents are currently the primary driver of rising drug costs in the United States.

Researchers apply a dynamic model to analyze demand response to non-linear drug benefits using data from Medicare Part D.